Circulating nucleic acids in plasma and serum: Diagnosis and prognosis in cancer

EPMA Journal

Volumn 1, Issue 3, 2010, Pages 503-512

  Gahan, Peter Brian ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Circulating DNA RNA; Diagnosis; Nucleic acid uptake expression; Personalized medicine; Plasma serum

Indexed keywords

CISPLATIN; DNA; DNA FRAGMENT; GEFITINIB; MICRORNA; NUCLEIC ACID; RNA; TEMOZOLOMIDE; VASCULOTROPIN RECEPTOR; VIRUS DNA;

BLOOD LEVEL; BLOOD SAMPLING; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; DISEASE ASSOCIATION; DNA EXTRACTION; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; NASOPHARYNX CANCER; NONHUMAN; NUCLEIC ACID ANALYSIS; NUCLEOSOME; OVARY CANCER; PERSONALIZED MEDICINE; PLASMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SERUM; TREATMENT OUTCOME; WART VIRUS;

EID: 79953045912     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-010-0021-6     Document Type: Review

References (100)

1. Mendel P, Métais P. Les acides nucléiques du plasma sanguine chez l'homme. CR Acad Sci Paris. 1948; 142: 241-3.
2. Watson JD, Crick FH. A structure for deoxyribose nucleic acid. Nature. 1953; 171: 737-8.
3. Wilkins MH, Stokes AR, Wilson HR. Molecular structure of deoxypentose nucleic acids. Nature. 1953; 171: 738-40.
4. Sinsheimer RL. First steps toward a genetic chemistry. Science. 1957; 125: 1123-8.
5. Koffler D, Agnello V, Winchester R. The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythrematosus and other diseases. J Clin Invest. 1973; 52: 198-204.
6. Tan EM, Schur PH, Carr RI, et al. Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythrematosus. J Clin Invest. 1966; 45: 1732-40.
7. Rainer TH, Wong LK, Lam W, et al. Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin Chem. 2003; 49: 562-9.
8. Lam NY, Rainer TH, Chan LY, et al. Time course of early and late changes in plasma DNA in trauma patients. Clin Chem. 2003; 49: 1286-91.
9. Chiu TW, Young R, Chan LYS, et al. Plasma cell-free DNA as an indicator of severity of injury in burn patients. Clin Hem Lab Manag. 2006; 44: 13-7.
10. Gahan PB. Circulation nucleic acids in plasma and serum: roles in diagnosis and prognosis in diabetes and cancer. Infect Disord Drug Targets. 2008; 8: 100-8.
11. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977; 37: 646-50.
12. Stroun M, Anker P, Maurice P, et al. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989; 46: 318-22.
13. Anker P, Stroun M, Maurice P. Spontaneous release of DNA by human blood lymphocytes as shown in an in vitro system. Cancer Res. 1975; 35: 2375-82.
14. Rykova EY, Bryzgunova OE, Skvortsova TE, Tamkovich TN, Senin IN, Laktionov PP, et al. Concentrations of circulating RNA from healthy donors and cancer patients. Ann NY Acad Sci. 2006; 1075: 328-33.
15. Holford NC, Ramoutar A, Butt AN, et al. Normalization of circulating nucleic acid results. Should we use β-actin? Ann NY Acad Sci. 2008; 1137: 112-8.
16. Gahan PB, Stroun M. The biology of circulating nucleic acids in plasma and serum. In: Rykova EY, Kikuchi Y, editors. Extracellular nucleic acids. In Series "Nucleic Acids and Molecular Biology" Springer Berlin; 2010, in press.
17. Gahan PB, Stroun M. The virtosome-a novel cytosolic informative entity & intercellular messenger. Cell Biochem Funct; 2010, submitted.
18. Gahan PB. Circulating nucleic acids in plasma and serum: roles in diagnosis and prognosis. In: Golubnitschaja O, editor. Predictive diagnostics and personalised treatment. Boston: Nova Science Publishers; 2009.
19. Tsui NB, Ng EK, Lo YMD. Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem. 2002; 48: 1647-53.
20. Holford NC, Sandhu HS, Thakkar H, et al. Stability of β-Actin mRNA in plasma. Ann NY Acad Sci. 2008; 1137: 108-11.
21. Board RE, Williams VS, Knight L, et al. Isolation and extraction of circulating tumor DNA from patients with small cell lung cancer. Ann NY Acad Sci. 2008; 1137: 98-107.
22. Page K, Powles T, Slade MJ, et al. The importance of careful blood processing in isolation of cell free DNA. Ann NY Acad Sci. 2006; 1075: 313.
23. Dovc-Drnovsek T, Emersic B, Rozman P. Optimisation of purification of human cell-free mRNA from plasma. Ann NY Acad Sci. 2008; 1137: 125-9.
24. Tamkovich SN, Litvjakov NV, Bryzgunova OE, et al. Cell-surface-bound circulating DNA as a prognostic factor in lung cancer. Ann NY Acad Sci. 2008; 1137: 214-7.
25. Fleischhacker M, Schmidt B, Weickmann S et al. Comparison of nucleosomes and quantitative PCR using diverse DNA isolation methods. In "Circulating Nucleic Acids in Plasma and Serum". Ed. PB Gahan. Berlin: Springer; 2010, in press.
26. Fong SL, Zhang JT, Lim CK. Comparison of 7 methods for extracting cell-free DNA from serum samples of colorectal cancer patients. Clin Chem. 2009; 55: 587-9.
27. Horlitz M, Hartinger T, Graf S, et al. Yields of viral and circulating cell-free nucleic acids using the QIAamp® circulating nucleic acid kit. In: Gahan PB, editor. Circulating nucleic acids in plasma and serum. Berlin: Springer; 2010. in press.
28. Krishnann R, Heller MJ. Rapid isolation and detection of cell free circulating DNA and other disease biomarkers directly from whole blood. In: Gahan PB, editor. Circulating nucleic acids in plasma and serum. Berlin: Springer; 2010. in press.
29. van der Vaart M, Pretorius PJ. A method for characterization of total circulating DNA. Ann NY Acad Sci. 2008; 1137: 92-7.
30. Lo YMD, Lun FMF, Chan KCA, et al. Digital PCR for the molecular detection of fetal chromosomal aneuploidy. Proc Natl Acad Sci USA. 2007; 104: 13116-21.
31. Holdenrieder S, Burges A, Reich O, et al. DNA integrity in plasma and serum of patients with malignant and benign diseases. Ann NY Acad Sci. 2008; 1137: 162-70.
32. Ciriglian V, Voglino G, Marongiu A, et al. Rapid prenatal diagnosis by QF-PCR: evaluation of 30, 000 consecutive clinical samples and future applications. Ann NY Acad Sci. 2006; 1075: 288-98.
33. Gole L, Adrianne F, Ee AM. Refining quantitative fluorescent polymerase chain reaction for prenatal detection of X chromosomal anomalies in the major Southeast Asian populations. Singapore Med J. 2008; 49: 1025-8.
34. Kyle D, Weaver MD, Stuart A, et al. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Investig. 2006; 24: 35-40.
35. Sunami E, Shinozaki M, Higano CS, et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem. 2009; 55: 559-67.
36. Lavon I, Refael M, Zelikovitch B, et al. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-Oncology. 2010; 12: 173-80.
37. Le Q-T, Jones CD, Yau T-K, et al. A comparison study of different PCR assays in measuring circulating plasma epstein-barr virus DNA levels in patients with nasopharyngeal carcinoma. Clin Cancer Res. 2005; 11: 5700-12.
38. Ding C, Lo YM. MALDI-TOF mass spectrometry for quantitative, specific, and sensitive analysis of DNA and RNA. Ann NY Acad Sci. 2006; 1075: 282-7.
39. Ming X, Phong A, Ha C, et al. Rapid DNA mapping by fluorescent single molecule detection. Nucleic Acids Res. 2007; 35(3): e16. doi: 10. 1093/nar/gkl1044.
40. Rogers YH, Ventner JC. Genomics: massively parallel sequencing. Nature. 2005; 437: 326-7.
41. Rossa WK, Sun CH, Akolekar R, et al. Maternal plasma DNA analysis with massively parallel sequencing by ligation for noninvasive prenatal diagnosis of trisomy 21. Clin Chem. 2010; 56: 459-63.
42. Umetani N, Kim J, Hiramats S, et al. Increased integrity of free circulating DNA in sera of patients with colorectal. Clin Chem. 2006; 52: 1062-9.
43. Chim SSC, Shing TKF, Hung ECW. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem. 2008; 54: 482-90.
44. Hung ECW, Chiu RWK, Lo YMD. Detection of circulating fetal nucleic acids: a review of methods and applications. J Clin Path. 2009; 62: 308-13.
45. Ji X, Takahashi R, Hiura Y, et al. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem. 2009; 55: 1944-9.
46. Lodes MJ, Caraballo M, Suciu D, et al. Detection of cancer with serum microRNAs on an oligonucleotide microarray. PLoS ONE. 2009; 14: e622.
47. Jiang WW, Zahurak M, Goldenberg D. Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer. 2007; 119: 2673-6.
48. Daniotti M, Vallacchi V, Rivoltini L, et al. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. Int J Cancer. 2007; 120: 2439-44.
49. Cheung ST, Fan ST, Lee YT, et al. Albumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma. Transplantation. 2008; 85: 81-7.
50. Gang F, Guorong L, An Z, et al. Prediction of clear cell renal cell carcinoma by integrity of cell-free DNA in serum. Urology. 2010; 75: 262-5.
51. Xue X, Zhu YM, Woll PA. circulating DNA in lung cancer. Ann NY Acad Sci. 2006; 1075: 154-64.
52. Schmidt B, Weickmann S, Witt C, et al. Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann NY Acad Sci. 2008; 1137: 207-13.
53. Sozzi G, Conte D, Leon ME. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol. 2003; 21: 3902-8.
54. Ponomaryova AA, Rykova EY, Cherdyntseva NV, et al. Concentration and distribution of single-copy β-actin gene and LINE-1 repetitive elements in blood of lung cancer patients. In: Gahan PB, editor. Circulating nucleic acids in plasma and serum. Berlin: Springer; 2010. in press.
55. Wang YC, Hsu HS, Chen TP, et al. Molecular diagnostic markers for lung cancer in sputum and plasma. Ann NY Acad Sci. 2006; 1075: 179-84.
56. Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small cell lung cancer. Clin Cancer Res. 2006; 13: 3915-21.
57. Holdenreider S, van Pawel J, Duell T, et al. Circulating nucleosomes and oncogenic biomarkers in monitoring chemotherapy of small cell lung cancer. In: Gahan PB, editor. Circulating nucleic acids in plasma and serum. Berlin: Springer; 2010. in press.
58. Ding Q, Mu Y, Pan S, et al. Plasma DNA methylation analysis in predicting short-term recurrence of surgical patients with non-small cell lung cancer (NSCLC). In: Gahan PB, editor. Circulating nucleic acids in plasma and serum. Berlin: Springer; 2010. in press.
59. Schwarzenbach H, Stoehlmacher J, Pantel K, et al. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann NY Acad Sci. 2008; 1137: 190196.
60. Sorenson GD. A review of studies on the detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Ann NY Acad Sci. 2000; 906: 13-6.
61. Su YH, Wang M, Brenner DE, et al. Detection of mutated K-ras in urine, plasma and serum of patients with colorectal carcinoma or adenomatous polyps. Ann NY Acad Sci. 2008; 1137: 197-206.
62. Ward R, Sheehan C, Norrie M, et al. Factors influencing the detection of mutant K-ras in the serum of patients with colorectal cancer. Ann NY Acad Sci. 2000; 906: 17-8.
63. Frattini M, Gallino G, Signoroni S, et al. Quantitative analysis of plasma DNA in colorectal cancer patients. Ann NY Acad Sci. 2006; 1075: 185-90.
64. Taback B, Saha S, Hoon DSB. Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer. Ann NY Acad Sci. 2006; 1075: 197-203.
65. Holdenrieder S, Nagel D, Schalhorn A. Clinical relevance of circulating nucleosomes in cancer. Ann NY Acad Sci. 2008; 1137: 180-9.
66. Deligezer U, Akisik EZ, Akisik EE, et al. H3K9me3/H4K20me3 ratio in circulating nucleosomes as potential biomarker for colorectal cancer. In: Gahan PB, editor. Circulating nucleic acids in plasma and serum. Berlin: Springer; 2010. in press.
67. Schetter AJ, Harris CC. Plasma microRNAs: potential biomarker for colorectal cancer? Gut. 2009; 58: 1318-9.
68. Ng EKO, Chong WWS, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009; 58: 1375-81. doi: 10. 1136/gut. 2008. 167817.
69. Zhong XY, Ladewig A, Schmid S, et al. Elevated level of cell-free plasma DNA is associated with breast cancer. Arch Gynecol Obstet. 2007; 276: 327-31.
70. Stoetzer OJ, Fersching DMI, Holdenrieder S. Circulating nucleosomes and DNAse in breast cancer patients during neoadjuvant chemotherapy. In: Gahan PB, editor. Circulating nucleic acids in plasma and serum. Berlin: Springer; 2010. in press.
71. Rykova EY, Tsvetovskaya GA, Sergeeva GI, et al. Methylation-based analysis of circulating DNA for breast tumor screening. Ann NY Acad Sci. 2008; 1137: 232-5.
72. Divella R, Tommasi S, Lacalamita R, et al. Circulating hTERT DNA in Early Breast Cancer. Anticancer Res. 2009; 29: 2845-9.
73. Contreros-Galindo R, Kaplan MH, Leissner P, et al. Human endogenous retrovirus K (HML-2) elements in the plasma of people with lymphoma and breast cancer. J Virol. 2008; 82: 9329-36.
74. Kamat A, Baldwi M, Urbauer D, et al. Plasma cell-free DNA in ovarian cancer. Cancer. 2010. doi: 10. 1002/cncr. 24997.
75. Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res. 2003; 63: 3966-8.
76. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol-Mech. 2009; 4: 287-313.
77. Boddy JL, Gal S, Malone PR, et al. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease. Clin Cancer Res. 2005; 11: 1394-9.
78. Muller I, Urban K, Pantel K, et al. Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign hyperplasia. Ann NY Acad Sci. 2006; 1075: 222-9.
79. Hoon DSB, Shinozaki M, Higano CS, et al. Circulating DNA serum biomarkers of different forms utility in evaluating prostate cancer patients. In: Gahan PB, editor. Circulating nucleic acids in plasma and serum. Berlin: Springer; 2010. in press.
80. Bryzgunova OE, Morozkin ES, Yarmoschuk SV, et al. Methylation-specific sequencing of GStP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients. Ann NY Acad Sci. 2008; 1137: 222-5.
81. Dasi F, Martinez-Rodes P, March JA, et al. Real-time quantification of human telomerase reverse transcriptase mRNA in the plasma of patients with prostate cancer. Ann NY Acad Sci. 2006; 1075: 204-10.
82. Schwarzenbach H, Alix-Panabières C, Müller I, et al. Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res. 2009; 15: 1032-8.
83. Balaña C, Ramirez JL, Taron M, et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1, 3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res. 2003; 9: 1461-8.
84. Holdenrieder S, Spuler A, Tischinger M, et al. Presence of nucleosomes in cerebrospinal fluid of glioblastoma patients-potential for therapy monitoring. In: Gahan PB, editor. Circulating nucleic acids in plasma and serum. Berlin: Springer; 2010. in press.
85. Skog J, Würdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumor growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10: 1470-6.
86. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Clin Cancer Res. 1999; 59: 1188-91.
87. Chan ATC, Teo PML, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol. 2002; 13: 1007-15.
88. Yang HJ, Liu VW, Tsang PC, et al. Quantification of human papilloma virus DNA in the plasma of patients with cervical cancer. Int J Gynecol. 2004; 14: 93-910.
89. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol. 2000; 53: 248-54.
90. Yang HJ, Liu VW, Tsang PC, et al. Quantification of human papilloma virus DN in the plasma of patients with cervical carcinoma. Int J Gynecol Cancer. 2004; 14: 903-10.
91. Adams DH, Gahan PB. Stimulated and non-stimulated rat spleen cells release different DNA-Sciences Genève complexes. Differentiation. 1982; 22: 47-52.
92. Adams DH, Gahan PB. The DNA extruded by rat spleen cells in culture. Int J Biochem. 1983; 15: 547-52.
93. Stroun M, Anker P, Gahan PB, Henri J. Spontaneous release of newly synthesized DNA from frog auricles. Arch Sci (Genève). 1977; 30: 229-42.
94. Anker P, Lyautey J, Lefort F, Lederrey C, Stroun M. Transformation of NIH/3T3 cells and SW 480 cells displaying K-ras mutation. CR Acad Sci III. 1994; 10: 869-74.
95. Adams DH, Diaz N, Gahan PB. In vitro stimulation by tumor cell media of [3H]thymidine incorporation by mouse spleen lymphocytes. Cell Biochem Funct. 1997; 15: 119-26.
96. García-Olmo DC, Domínguez C, García-Arranz M, et al. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells. Cancer Res. 2010; 70: 560-7.
97. García-Olmo D, García-Olmo DC, Ontañón J, et al. Tumor DNA circulating in the plasma might play a role in metastasis. The hypothesis of genometastasis. Histol Histopathol. 1999; 14: 1159-64.
98. García-Olmo D, García-Olmo DC, Ontañón J, et al. Horizontal transfer of DNA and the "genometastasis hypothesis". Blood. 2000; 95: 724-5.
99. Garcia-Olmo DC, Ruiz-Piqueras R, Garcia-Olmo D. Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol Histopathol. 2004; 19: 575-83.
100. Serrano-Heras G, García-Olmo D, García-Olmo DC. Microvesicles circulating in plasma of rats contain DNA. Are these small vesicles a main source of cell-free DNA in plasma? In: Gahan PB, editor. Circulating nucleic acids in plasma and serum. Berlin: Springer; 2010. in press.